Paul Taylor

1.7k total citations · 1 hit paper
32 papers, 900 citations indexed

About

Paul Taylor is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, Paul Taylor has authored 32 papers receiving a total of 900 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 5 papers in Epidemiology. Recurrent topics in Paul Taylor's work include Occupational and environmental lung diseases (15 papers), Pleural and Pulmonary Diseases (9 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (5 papers). Paul Taylor is often cited by papers focused on Occupational and environmental lung diseases (15 papers), Pleural and Pulmonary Diseases (9 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (5 papers). Paul Taylor collaborates with scholars based in United Kingdom, United States and Italy. Paul Taylor's co-authors include Dean A. Fennell, Arnaud Scherpereel, Anna K. Nowak, Hedy L. Kindler, S. Cedrés, Joachim G.J.V. Aerts, Federica Grosso, Alessandra Bearz, Kristiaan Nackaerts and M. Puglisi and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and British Journal of Cancer.

In The Last Decade

Paul Taylor

31 papers receiving 890 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

2017 304 citations Michele Maio, Arnaud Scherpereel et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul Taylor United Kingdom	14	566	347	134	101	90	32	900
Jeltje F. de Vries Netherlands	10	669 1.2×	747 2.2×	122 0.9×	54 0.5×	37 0.4×	15	1.2k
Paola Marroni Italy	14	284 0.5×	259 0.7×	174 1.3×	19 0.2×	98 1.1×	40	679
Matteo Perrino Italy	15	372 0.7×	166 0.5×	137 1.0×	50 0.5×	37 0.4×	48	670
Suchita Pakkala United States	15	522 0.9×	685 2.0×	154 1.1×	20 0.2×	106 1.2×	32	973
Anya M. Litvak United States	12	243 0.4×	596 1.7×	233 1.7×	36 0.4×	335 3.7×	15	900
Mitsunori Higuchi Japan	14	250 0.4×	275 0.8×	126 0.9×	16 0.2×	39 0.4×	77	654
Yang Feng China	9	287 0.5×	653 1.9×	103 0.8×	52 0.5×	184 2.0×	18	805
Emmanuelle Samalin France	16	353 0.6×	562 1.6×	137 1.0×	16 0.2×	111 1.2×	75	827
Carla M. van Herpen Netherlands	14	146 0.3×	325 0.9×	195 1.5×	16 0.2×	55 0.6×	27	608
Murali Rajaraman Canada	13	115 0.2×	206 0.6×	251 1.9×	38 0.4×	60 0.7×	28	845

Countries citing papers authored by Paul Taylor

Since Specialization

Citations

This map shows the geographic impact of Paul Taylor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Taylor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Taylor more than expected).

Fields of papers citing papers by Paul Taylor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Taylor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Taylor. The network helps show where Paul Taylor may publish in the future.

Co-authorship network of co-authors of Paul Taylor

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Taylor. A scholar is included among the top collaborators of Paul Taylor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Taylor. Paul Taylor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fornacon-Wood, Isabella, Raffaele Califano, Margaret Harris, et al.. (2024). A study demonstrating users’ preference for the adapted-REQUITE patient-reported outcome questionnaire over PRO-CTCAE® in patients with lung cancer. Frontiers in Oncology. 14. 1328871–1328871. 4 indexed citations

Fennell, Dean A., Daniel E. Griffiths, Zina Eminton, et al.. (2023). Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres. BMJ Open. 13(11). e073120–e073120. 2 indexed citations

Fennell, Dean A., J.F. Lester, Sarah Danson, et al.. (2022). Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial. EClinicalMedicine. 48. 101432–101432. 17 indexed citations

Zauderer, Marjorie G., Peter W. Szlosarek, Sylvestre Le Moulec, et al.. (2022). EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. The Lancet Oncology. 23(6). 758–767. 85 indexed citations

Lévy, Antonin, C. Le Péchoux, Hitesh Mistry, et al.. (2018). Prophylactic Cranial Irradiation for Limited-Stage Small-Cell Lung Cancer Patients: Secondary Findings From the Prospective Randomized Phase 3 CONVERT Trial. Journal of Thoracic Oncology. 14(2). 294–297. 15 indexed citations

Grosso, Federica, Nicola Steele, Silvia Novello, et al.. (2017). Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. Journal of Clinical Oncology. 35(31). 3591–3600. 77 indexed citations

Maio, Michele, Arnaud Scherpereel, Luana Calabrò, et al.. (2017). Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. The Lancet Oncology. 18(9). 1261–1273. 304 indexed citations breakdown →

Tang, Mila, Ognjenka Djurdjev, Mhairi K. Sigrist, et al.. (2012). Vascular stiffness in incident peritoneal dialysis patients over time. Clinical Nephrology. 78(10). 254–262. 8 indexed citations

Faivre‐Finn, Corinne, Fiona Blackhall, Linda Ashcroft, et al.. (2011). Long-term Toxicity Report From a Phase II Study of Accelerated Twice-Daily (BD) versus High Dose Once-Daily (OD) Thoracic Radiotherapy (RT) With Concurrent Chemotherapy for Limited-Stage Small Cell Lung Cancer (LS-SCLC). International Journal of Radiation Oncology*Biology*Physics. 81(2). S589–S589. 3 indexed citations

10.

Colaco, Rovel, Paul Lorigan, Fiona Blackhall, et al.. (2011). Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer – Evidence from a phase II trial. Lung Cancer. 76(1). 72–77. 25 indexed citations

11.

Taylor, Paul, B. Castagneto, G. Dark, et al.. (2008). Single-Agent Pemetrexed for Chemonaïve and Pretreated Patients with Malignant Pleural Mesothelioma: Results of an International Expanded Access Program. Journal of Thoracic Oncology. 3(7). 764–771. 39 indexed citations

12.

Faivre‐Finn, Corinne, Fiona Blackhall, N. Thatcher, et al.. (2008). Feasibility and toxicity report from a phase II study of accelerated twice-daily (BDRT) versus high dose once-daily thoracic radiotherapy (ODRT) with concurrent chemotherapy for limited stage small cell lung cancer (LS-SCLC). Journal of Clinical Oncology. 26(15_suppl). 7583–7583. 2 indexed citations

13.

Baka, Sofia, Raffaele Califano, Roberta Ferraldeschi, et al.. (2008). Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. British Journal of Cancer. 99(3). 442–447. 42 indexed citations

14.

Gatzemeier, U., Paul Taylor, Joachim von Pawel, et al.. (2007). C5-03: Open-label study of pemetrexed alone or in combination with a platinum for previously treated patients (pts) with malignant pleural mesothelioma (MPM): Outcomes from the International Expanded Access Program (EAP). Journal of Thoracic Oncology. 2(8). S372–S373. 2 indexed citations

15.

Blackhall, Fiona, Paul Taylor, Linda Ashcroft, et al.. (2007). B2-06: A pragmatic, randomised study to compare the hospitalisation rates of two platinum-based outpatient regimens (Gemicitabine/Cisplatin vs. Gemcitabine/Carboplatin) in non-small cell lung cancer (NSCLC) - UK Swiss collaboration. Journal of Thoracic Oncology. 2(8). S338–S338. 2 indexed citations

16.

Rajiah, Prabhakar, et al.. (2006). Renal transplant imaging and complications. Abdominal Imaging. 31(6). 735–746. 20 indexed citations

17.

Alberdi, Eugenio, Paul Taylor, Richard Lee, John Fox, & Andrew Todd‐Pokropek. (2002). Eliciting a Terminology for Mammographic Calcifications. Clinical Radiology. 57(11). 1007–1013. 5 indexed citations

18.

Taylor, Paul, et al.. (1999). The development and evaluation of CADMIUM: a prototype system to assist in the interpretation of mammograms. Medical Image Analysis. 3(4). 321–337. 23 indexed citations

19.

Starzl, Thomas E., et al.. (1990). Long-term (25-year) survival after renal homotransplantation--the world experience.. PubMed. 22(5). 2361–5. 22 indexed citations

20.

Thatcher, N., et al.. (1989). Interleukin-2 in malignant pleural mesothelioma (and adenocarcinoma of the lung). The use of intrapleural and continuous intravenous infusions: preliminary results. Cancer Treatment Reviews. 16. 161–162. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact